title: Challenges in the therapy of HIV infection.
abstract: Drugs that inhibit human immunodeficiency virus (HIV) replication have been shown to have clinical utility in patients with HIV infection. However, the immunological improvement induced by available anti-HIV therapies in patients with acquired immune deficiency syndrome (AIDS) is incomplete and transient. Explanations for this may include immunological barriers to complete reconstitution, low therapeutic indices of the available drugs, and the development of viral resistance. An understanding of these processes, as discussed here by Robert Yarchoan and colleagues, may provide important leads for the development of improved therapy for AIDS.
authors.affiliation: Retroviral Diseases Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
authors.forename: R
authors.initials: R
authors.lastname: Yarchoan
authors.forename: H
authors.initials: H
authors.lastname: Mitsuya
authors.forename: S
authors.initials: S
authors.lastname: Broder
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000628:therapy*; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015224:Dideoxynucleosides / Q000494:pharmacology / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D006678:HIV / Q000187:drug effects*; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D017320:HIV Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D015224:Dideoxynucleosides; D017320:HIV Protease Inhibitors